Rating Change
HC Wainwright & Co. reiterated its Buy rating on 4D Molecular Therapeutics, Inc. Common Stock (NASDAQ:FDMT) on October 22, 2026.
reiterateNASDAQ:FDMT
HC Wainwright & Co. Reiterates Buy Rating on 4D Molecular Therapeutics, Inc. Common Stock (FDMT)
HC Wainwright & Co. reiterated its Buy rating on 4D Molecular Therapeutics, Inc.
At publication ·
What changed
4D Molecular Therapeutics, Inc. Common Stock (NASDAQ:FDMT) · reiterate
- Firm
- HC Wainwright & Co.
- Rating
- Buy to Buy
- Price at event
- $11.85
- Market capitalization
- $510.5M
At a glance
Key takeaways
- HC Wainwright & Co. reiterated a Buy rating on 4D Molecular Therapeutics (FDMT) on October 22, 2026.
Market Context
4D Molecular Therapeutics, Inc. Common Stock operates in the Healthcare sector. The stock currently trades at $11.85 with a market capitalization of $510.5M. The stock has gained 12.0% over the past 52 weeks.
Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for 4D Molecular Therapeutics, Inc. Common Stock.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for 4D Molecular Therapeutics, Inc. Common Stock
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 22, 2026 | HC Wainwright & Co. | Buy | N/A |
| Oct 06, 2026 | Chardan Capital | Buy | N/A |
| Sep 29, 2026 | B of A Securities | Buy | N/A |
| Sep 14, 2026 | Cantor Fitzgerald | Overweight | N/A |
| Jul 31, 2026 | B. Riley Securities | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View FDMT Stock Page
Frequently Asked Questions
What does the Buy rating mean for FDMT?
A rating of Buy from HC Wainwright & Co. reflects the analyst's outlook on 4D Molecular Therapeutics, Inc. Common Stock (NASDAQ:FDMT). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the FDMT forecast page.